HealthyNCT06347627
Communicating Human Papillomavirus Vaccine With Japanese Parents and Caregivers With Daughters Aged 12-18
A study testing Group 1 (I x S x S x F), Group 2 (O x S x S x F) and Group 3 (I x E x S x F) in people with Healthy, run by The University of Hong Kong at 1 site in United Kingdom.
Trial summary
This study aims to comprehensively assess confidence in and acceptance of human papillomavirus (HPV) vaccines among Japanese parents and caregivers with daughters aged 12-18 and their decision-making process. Read more about this study
- Who is it for?
- Ages 20 years and older, women onlyHealthy volunteers can take part
- Conditions the study is for
- Healthy
- What is being tested?
- Group 1 (I x S x S x F), Group 2 (O x S x S x F) and Group 3 (I x E x S x F)
- Type of treatment
- Vaccines, Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,324 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 22 Dec 2023to 22 Jan 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 years and older
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Female adult caregivers, older than 20, with daughters aged 12-18 who have received none or only one shot of HPV vaccine.
Who cannot join
- Caregivers who do not agree to participate in survey, experiment, or both.
- Caregivers with daughters who have already received two or more HPV vaccines.
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site
London School of Hygiene and Tropical Medicine
London
About this study
Official title: Communicating Human Papillomavirus Vaccine With Japanese Parents and Caregivers With Daughters Aged 12-18: a Mixed-methods Assessment of Acceptance of HPV Vaccine With Experiments on Communication Strategies
This study aims to comprehensively assess confidence in and acceptance of human papillomavirus (HPV) vaccines among Japanese parents and caregivers with daughters aged 12-18 and their decision-making process.
Read the detailed description
This study will implement an experiment as a sixteen-arm randomized controlled trial in an online survey environment. Before the experiment, participants, who are Japanese caregivers with daughters aged 12-18 who have not received an HPV vaccine, will first answer a pre-experiment survey. The survey will collect information on participants' socio-demographic data and key decision-making factors for HPV vaccine acceptance and confidence. Then, the study will randomly assign the participants to view one digital communication message using a 2 × 2 × 2 × 2 between-person factorial experiment on 'components of message.' The sixteen experimental messages will be developed based on real social media messages posted between November 2021 and April 2022, when the Japanese government prepared to reinstate an active recommendation of HPV vaccines for eligible girls after eight and a half years of suspension.
The sixteen messages will assess four factors: messenger, style, content, and misinformation. Each message will be similar except for one variable in consideration. The messenger component will be whether the message is from an individual or an organization. As individual messengers, the study will set a fictional male or female with common Japanese names who actively communicate about HPV vaccines. As organizational messengers, the study will use the existing accounts of the Ministry of Health, Labour and Welfare or the Japan Cancer Society or a fictional account of an anti-vaccine group. The style component will be whether the message conveys information through storytelling or scientific data. Messages will include personal stories for the storytelling style and statistics for the scientific data style. The content component will be whether the message conveys information about the effectiveness of the HPV vaccine in preventing diseases or the safety of the HPV vaccine. The contents will be built on both factual information and misconceptions about HPV vaccine safety and effectiveness that are often mentioned in the actual social media posts. The misinformation component will be whether the message conveys misinformation or factual information. The study will debrief all respondents exposed to misinformation after the survey.
Lastly, the study will collect data as a post-experiment survey to evaluate how an online message influenced caregivers' trust, confidence, and motivation to vaccinate.
- Conditions
- Healthy
- Being tested
- Group 1 (I x S x S x F), Group 2 (O x S x S x F), Group 3 (I x E x S x F), Group 4 (O x E x S x F), Group 5 (I x S x S x M)
- Keywords
- HPV Vaccine
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Group 1 (I x S x S x F)Behavioural
Experimental message: Individual x Safety x Storytelling x Factual
Group 2 (O x S x S x F)Behavioural
Experimental message: Organization x Safety x Storytelling x Factual
Group 3 (I x E x S x F)Behavioural
Experimental message: Individual x Effectiveness x Storytelling x Factual
Group 4 (O x E x S x F)Behavioural
Experimental message: Organization x Effectiveness x Storytelling x Factual
Group 5 (I x S x S x M)Behavioural
Experimental message: Individual x Safety x Storytelling x Misinformation
Group 6 (O x S x S x M)Behavioural
Experimental message: Organization x Safety x Storytelling x Misinformation
Group 7 (I x E x S x M)Behavioural
Experimental message: Individual x Effectiveness x Storytelling x Misinformation
Group 8 (O x E x S x M)Behavioural
Experimental message: Organization x Effectiveness x Storytelling x Misinformation
Group 9 (I x S x D x F)Behavioural
Experimental message: Individual x Safety x Scientific data x Factual
Group 10 (O x S x D x F)Behavioural
Experimental message: Organization x Safety x Scientific data x Factual
Group 11 (I x E x D x F)Behavioural
Experimental message: Individual x Effectiveness x Scientific data x Factual
Group 12 (O x E x D x F)Behavioural
Experimental message: Organization x Effectiveness x Scientific data x Factual
Group 13 (I x S x D x M)Behavioural
Experimental message: Individual x Safety x Scientific data x Misinformation
Group 14 (O x S x D x M)Behavioural
Experimental message: Organization x Safety x Scientific data x Misinformation
Group 15 (I x E x D x M)Behavioural
Experimental message: Individual x Effectiveness x Scientific data x Misinformation
Group 16 (O x E x D x M)Behavioural
Experimental message: Organization x Effectiveness x Scientific data x Misinformation
| Study group | Role | What they receive |
|---|---|---|
| Group 1 (I x S x S x F) | Experimental | Participants in Group 1 will view a message in an X (former Twitter) format composed of "Individual x Safety x Storytelling x Factual" factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate. Receives: Behavioral: Group 1 (I x S x S x F) |
| Group 2 (O x S x S x F) | Experimental | Participants in Group 2 will view a message in an X (former Twitter) format composed of "Organization x Safety x Storytelling x Factual" factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate. Receives: Behavioral: Group 2 (O x S x S x F) |
| Group 3 (I x E x S x F) | Experimental | Participants in Group 3 will view a message in an X (former Twitter) format composed of "Individual x Effectiveness x Storytelling x Factual" factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate. Receives: Behavioral: Group 3 (I x E x S x F) |
| Group 4 (O x E x S x F) | Experimental | Participants in Group 4 will view a message in an X (former Twitter) format composed of "Organization x Effectiveness x Storytelling x Factual" factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate. Receives: Behavioral: Group 4 (O x E x S x F) |
| Group 5 (I x S x S x M) | Experimental | Participants in Group 5 will view a message in an X (former Twitter) format composed of "Individual x Safety x Storytelling x Misinformation" factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate. Receives: Behavioral: Group 5 (I x S x S x M) |
| Group 6 (O x S x S x M) | Experimental | Participants in Group 6 will view a message in an X (former Twitter) format composed of "Organization x Safety x Storytelling x Misinformation" factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate. Receives: Behavioral: Group 6 (O x S x S x M) |
| Group 7 (I x E x S x M) | Experimental | Participants in Group 7 will view a message in an X (former Twitter) format composed of "Individual x Effectiveness x Storytelling x Misinformation" factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate. Receives: Behavioral: Group 7 (I x E x S x M) |
| Group 8 (O x E x S x M) | Experimental | Participants in Group 8 will view a message in an X (former Twitter) format composed of "Organization x Effectiveness x Storytelling x Misinformation" factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate. Receives: Behavioral: Group 8 (O x E x S x M) |
| Group 9 (I x S x D x F) | Experimental | Participants in Group 9 will view a message in an X (former Twitter) format composed of "Individual x Safety x Scientific data x Factual" factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate. Receives: Behavioral: Group 9 (I x S x D x F) |
| Group 10 (O x S x D x F) | Experimental | Participants in Group 10 will view a message in an X (former Twitter) format composed of "Organization x Safety x Scientific data x Factual" factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate. Receives: Behavioral: Group 10 (O x S x D x F) |
| Group 11 (I x E x D x F) | Experimental | Participants in Group 11 will view a message in an X (former Twitter) format composed of "Individual x Effectiveness x Scientific data x Factual" factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate. Receives: Behavioral: Group 11 (I x E x D x F) |
| Group 12 (O x E x D x F) | Experimental | Participants in Group 12 will view a message in an X (former Twitter) format composed of "Organization x Effectiveness x Scientific data x Factual" factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate. Receives: Behavioral: Group 12 (O x E x D x F) |
| Group 13 (I x S x D x M) | Experimental | Participants in Group 13 will view a message in an X (former Twitter) format composed of "Individual x Safety x Scientific data x Misinformation" factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate. Receives: Behavioral: Group 13 (I x S x D x M) |
| Group 14 (O x S x D x M) | Experimental | Participants in Group 14 will view a message in an X (former Twitter) format composed of "Organization x Safety x Scientific data x Misinformation" factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate. Receives: Behavioral: Group 14 (O x S x D x M) |
| Group 15 (I x E x D x M) | Experimental | Participants in Group 15 will view a message in an X (former Twitter) format composed of "Individual x Effectiveness x Scientific data x Misinformation" factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate. Receives: Behavioral: Group 15 (I x E x D x M) |
| Group 16 (O x E x D x M) | Experimental | Participants in Group 16 will view a message in an X (former Twitter) format composed of "Organization x Effectiveness x Scientific data x Misinformation" factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate. Receives: Behavioral: Group 16 (O x E x D x M) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Willingness to receive HPV vaccines for daughters
A degree of a change in willingness to receive HPV vaccines after viewing an experimental message will be scored on a 5-point scale. The options are 1) much less willing to get the HPV vaccine for my daughter, 2) somewhat less, 3) neither more or less, 4) somewhat more, and 5) much more, with higher scores indicating a better outcome.
Measured: This experiment is expected to take 20-30 minutes to complete. The study will assess the outcome measure immediately after participants are exposed to the experimental messages.
Secondary outcomes (1)
Confidence in HPV vaccine safety
A degree of a change in confidence regarding HPV vaccine safety after viewing an experimental message will be scored on a 5-point scale. The options are 1) much less confident that the HPV vaccine is safe, 2) somewhat less, 3) neither more or less, 4) somewhat more, and 5) much more, with higher scores indicating a better outcome.
Measured: This experiment is expected to take 20-30 minutes to complete. The study will assess the outcome measure immediately after participants are exposed to the experimental messages.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Apr 2024
- Study start22 Dec 2023
- Primary completion22 Jan 2024
- Study completion22 Jan 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for HealthyStudies of the same condition, open and under way.
- More trials run by The University of Hong KongThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 1,324 participants (actual)
Sponsor and investigators
- Lead sponsor
- The University of Hong Kong
- Sponsor type
- University, hospital or other
- Collaborators
- London School of Hygiene and Tropical Medicine, Nagasaki University
- Responsible party
- Sponsor
- Investigators
- Leesa Lin, PhD, Principal investigator, London School of Hygiene and Tropical Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06347627
- Sponsor's protocol ID
- UW23139
- Status last verified
- Apr 2026
- First submitted
- 17 Mar 2024
- Last updated
- 15 May 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Kobayashi K, Masuda K, Wu JT, Lin L. Impact of digital communication message on HPV vaccine decision-making among Japanese mothers: A randomized controlled trial. Vaccine. 2025 Aug 13;61:127327. doi: 10.1016/j.vaccine.2025.127327. Epub 2025 Jun 3.
PubMed 40466485
Study at a glance
From the registry record, last updated by the sponsor on 15 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Communicating Human Papillomavirus Vaccine With Japanese Parents and Caregivers With Daughters Aged 12-18: a Mixed-methods Assessment of Acceptance of HPV Vaccine With Experiments on Communication Strategies
- ClinicalTrials.gov ID
- NCT06347627
- Acronym / sponsor ID
- UW23139
- Conditions
- Healthy
- Keywords
- HPV Vaccine
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 1,324 participants (actual)
- Lead sponsor
- The University of Hong KongUniversity, hospital or other
- Collaborators
- London School of Hygiene and Tropical Medicine, Nagasaki University
- Study start
- 22 Dec 2023 (actual)
- Primary completion
- 22 Jan 2024 (actual)
- Study completion
- 22 Jan 2024 (actual)
- First posted
- 4 Apr 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to comprehensively assess confidence in and acceptance of human papillomavirus (HPV) vaccines among Japanese parents and caregivers with daughters aged 12-18 and their decision-making process.
Detailed description
This study will implement an experiment as a sixteen-arm randomized controlled trial in an online survey environment. Before the experiment, participants, who are Japanese caregivers with daughters aged 12-18 who have not received an HPV vaccine, will first answer a pre-experiment survey. The survey will collect information on participants' socio-demographic data and key decision-making factors for HPV vaccine acceptance and confidence. Then, the study will randomly assign the participants to view one digital communication message using a 2 × 2 × 2 × 2 between-person factorial experiment on 'components of message.' The sixteen experimental messages will be developed based on real social media messages posted between November 2021 and April 2022, when the Japanese government prepared to reinstate an active recommendation of HPV vaccines for eligible girls after eight and a half years of suspension.
The sixteen messages will assess four factors: messenger, style, content, and misinformation. Each message will be similar except for one variable in consideration. The messenger component will be whether the message is from an individual or an organization. As individual messengers, the study will set a fictional male or female with common Japanese names who actively communicate about HPV vaccines. As organizational messengers, the study will use the existing accounts of the Ministry of Health, Labour and Welfare or the Japan Cancer Society or a fictional account of an anti-vaccine group. The style component will be whether the message conveys information through storytelling or scientific data. Messages will include personal stories for the storytelling style and statistics for the scientific data style. The content component will be whether the message conveys information about the effectiveness of the HPV vaccine in preventing diseases or the safety of the HPV vaccine. The contents will be built on both factual information and misconceptions about HPV vaccine safety and effectiveness that are often mentioned in the actual social media posts. The misinformation component will be whether the message conveys misinformation or factual information. The study will debrief all respondents exposed to misinformation after the survey.
Lastly, the study will collect data as a post-experiment survey to evaluate how an online message influenced caregivers' trust, confidence, and motivation to vaccinate.
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 16
| Arm | Type | Receives |
|---|---|---|
| Group 1 (I x S x S x F) | Experimental | Behavioral: Group 1 (I x S x S x F)Participants in Group 1 will view a message in an X (former Twitter) format composed of "Individual x Safety x Storytelling x Factual" factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate. |
| Group 2 (O x S x S x F) | Experimental | Behavioral: Group 2 (O x S x S x F)Participants in Group 2 will view a message in an X (former Twitter) format composed of "Organization x Safety x Storytelling x Factual" factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate. |
| Group 3 (I x E x S x F) | Experimental | Behavioral: Group 3 (I x E x S x F)Participants in Group 3 will view a message in an X (former Twitter) format composed of "Individual x Effectiveness x Storytelling x Factual" factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate. |
| Group 4 (O x E x S x F) | Experimental | Behavioral: Group 4 (O x E x S x F)Participants in Group 4 will view a message in an X (former Twitter) format composed of "Organization x Effectiveness x Storytelling x Factual" factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate. |
| Group 5 (I x S x S x M) | Experimental | Behavioral: Group 5 (I x S x S x M)Participants in Group 5 will view a message in an X (former Twitter) format composed of "Individual x Safety x Storytelling x Misinformation" factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate. |
| Group 6 (O x S x S x M) | Experimental | Behavioral: Group 6 (O x S x S x M)Participants in Group 6 will view a message in an X (former Twitter) format composed of "Organization x Safety x Storytelling x Misinformation" factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate. |
| Group 7 (I x E x S x M) | Experimental | Behavioral: Group 7 (I x E x S x M)Participants in Group 7 will view a message in an X (former Twitter) format composed of "Individual x Effectiveness x Storytelling x Misinformation" factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate. |
| Group 8 (O x E x S x M) | Experimental | Behavioral: Group 8 (O x E x S x M)Participants in Group 8 will view a message in an X (former Twitter) format composed of "Organization x Effectiveness x Storytelling x Misinformation" factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate. |
| Group 9 (I x S x D x F) | Experimental | Behavioral: Group 9 (I x S x D x F)Participants in Group 9 will view a message in an X (former Twitter) format composed of "Individual x Safety x Scientific data x Factual" factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate. |
| Group 10 (O x S x D x F) | Experimental | Behavioral: Group 10 (O x S x D x F)Participants in Group 10 will view a message in an X (former Twitter) format composed of "Organization x Safety x Scientific data x Factual" factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate. |
| Group 11 (I x E x D x F) | Experimental | Behavioral: Group 11 (I x E x D x F)Participants in Group 11 will view a message in an X (former Twitter) format composed of "Individual x Effectiveness x Scientific data x Factual" factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate. |
| Group 12 (O x E x D x F) | Experimental | Behavioral: Group 12 (O x E x D x F)Participants in Group 12 will view a message in an X (former Twitter) format composed of "Organization x Effectiveness x Scientific data x Factual" factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate. |
| Group 13 (I x S x D x M) | Experimental | Behavioral: Group 13 (I x S x D x M)Participants in Group 13 will view a message in an X (former Twitter) format composed of "Individual x Safety x Scientific data x Misinformation" factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate. |
| Group 14 (O x S x D x M) | Experimental | Behavioral: Group 14 (O x S x D x M)Participants in Group 14 will view a message in an X (former Twitter) format composed of "Organization x Safety x Scientific data x Misinformation" factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate. |
| Group 15 (I x E x D x M) | Experimental | Behavioral: Group 15 (I x E x D x M)Participants in Group 15 will view a message in an X (former Twitter) format composed of "Individual x Effectiveness x Scientific data x Misinformation" factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate. |
| Group 16 (O x E x D x M) | Experimental | Behavioral: Group 16 (O x E x D x M)Participants in Group 16 will view a message in an X (former Twitter) format composed of "Organization x Effectiveness x Scientific data x Misinformation" factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate. |
Who may qualify
- Ages
- 20 years and older
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Female adult caregivers, older than 20, with daughters aged 12-18 who have received none or only one shot of HPV vaccine.
Key exclusion criteria (2 listed)
- Caregivers who do not agree to participate in survey, experiment, or both.
- Caregivers with daughters who have already received two or more HPV vaccines.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Group 1 (I x S x S x F)Experimental message: Individual x Safety x Storytelling x Factual | Behavioural | Group 1 (I x S x S x F) |
| Group 2 (O x S x S x F)Experimental message: Organization x Safety x Storytelling x Factual | Behavioural | Group 2 (O x S x S x F) |
| Group 3 (I x E x S x F)Experimental message: Individual x Effectiveness x Storytelling x Factual | Behavioural | Group 3 (I x E x S x F) |
| Group 4 (O x E x S x F)Experimental message: Organization x Effectiveness x Storytelling x Factual | Behavioural | Group 4 (O x E x S x F) |
| Group 5 (I x S x S x M)Experimental message: Individual x Safety x Storytelling x Misinformation | Behavioural | Group 5 (I x S x S x M) |
| Group 6 (O x S x S x M)Experimental message: Organization x Safety x Storytelling x Misinformation | Behavioural | Group 6 (O x S x S x M) |
| Group 7 (I x E x S x M)Experimental message: Individual x Effectiveness x Storytelling x Misinformation | Behavioural | Group 7 (I x E x S x M) |
| Group 8 (O x E x S x M)Experimental message: Organization x Effectiveness x Storytelling x Misinformation | Behavioural | Group 8 (O x E x S x M) |
| Group 9 (I x S x D x F)Experimental message: Individual x Safety x Scientific data x Factual | Behavioural | Group 9 (I x S x D x F) |
| Group 10 (O x S x D x F)Experimental message: Organization x Safety x Scientific data x Factual | Behavioural | Group 10 (O x S x D x F) |
| Group 11 (I x E x D x F)Experimental message: Individual x Effectiveness x Scientific data x Factual | Behavioural | Group 11 (I x E x D x F) |
| Group 12 (O x E x D x F)Experimental message: Organization x Effectiveness x Scientific data x Factual | Behavioural | Group 12 (O x E x D x F) |
| Group 13 (I x S x D x M)Experimental message: Individual x Safety x Scientific data x Misinformation | Behavioural | Group 13 (I x S x D x M) |
| Group 14 (O x S x D x M)Experimental message: Organization x Safety x Scientific data x Misinformation | Behavioural | Group 14 (O x S x D x M) |
| Group 15 (I x E x D x M)Experimental message: Individual x Effectiveness x Scientific data x Misinformation | Behavioural | Group 15 (I x E x D x M) |
| Group 16 (O x E x D x M)Experimental message: Organization x Effectiveness x Scientific data x Misinformation | Behavioural | Group 16 (O x E x D x M) |
Primary outcome
Willingness to receive HPV vaccines for daughters
Time frame: This experiment is expected to take 20-30 minutes to complete. The study will assess the outcome measure immediately after participants are exposed to the experimental messages.
A degree of a change in willingness to receive HPV vaccines after viewing an experimental message will be scored on a 5-point scale. The options are 1) much less willing to get the HPV vaccine for my daughter, 2) somewhat less, 3) neither more or less, 4) somewhat more, and 5) much more, with higher scores indicating a better outcome.
1 secondary outcome
Confidence in HPV vaccine safety
Time frame: This experiment is expected to take 20-30 minutes to complete. The study will assess the outcome measure immediately after participants are exposed to the experimental messages.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 May 2026.
- Derived from this study: PubMed 40466485Kobayashi K, Masuda K, Wu JT, Lin L. Impact of digital communication message on HPV vaccine decision-making among Japanese mothers: A randomized controlled trial. Vaccine. 2025 Aug 13;61:127327. doi: 10.1016/j.vaccine.2025.127327. Epub 2025 Jun 3.
Related trials for Healthy
Recruiting
THE EFFECTS OF GAME-BASED EXERCISE PROGRAMS
Physical Activity, Body Image
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
Not yet recruiting
Neuroergonomic Analysis of a Brain-Computer Interface Device (BCI)
Healthy Volunteers - Male and Female
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Leesa Lin, PhD principal investigator
London School of Hygiene and Tropical Medicine
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Group 1 (I x S x S x F), Group 2 (O x S x S x F) and Group 3 (I x E x S x F) in people with Healthy, run by The University of Hong Kong at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Willingness to receive HPV vaccines for daughters (time frame: This experiment is expected to take 20-30 minutes to complete. The study will assess the outcome measure immediately after participants are exposed to the experimental messages.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06347627, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 May 2026.